CELU

Celularity Inc.

Regulated industry Physical products Sells to businesses Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $1.38
52-Week Range: $0.56 – $2.55
Market Cap: $51.92M
P/E (TTM): —
EPS (TTM): -2.73
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: —
PEG Ratio: —
Return on Equity: —
Return on Assets: -32.32%
Gross Margin: 5.26%
Operating Margin: -263.47%
Profit Margin: 0.00%
Current Ratio: 0.09
Debt/Equity: —
Total Debt: $68.08M
Free Cash Flow: $-1.36M
Revenue Growth: -66.30%
Earnings Growth: —
Enterprise Value: $119.63M

CELU Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$17.98M	$22.77M	$54.22M	$26.55M
Cost of Revenue	$19.66M	$16.02M	$14.99M	$20.07M
Gross Profit	-$1.69M	$6.75M	$39.23M	$6.48M
Research & Development	$78.36M	$30.46M	$17.39M	$15.03M
Selling, General & Admin	$66.02M	$50.58M	$58.64M	$51.27M
Operating Expenses	$146.58M	$83.23M	$77.78M	$67.78M
Operating Income	-$148.27M	-$76.48M	-$38.55M	-$61.31M
EBITDA	$23.64M	-$183.95M	-$43.71M	-$77.66M
Pretax Income	$14.21M	-$196.28M	-$57.89M	-$91.71M
Income Tax	$13.00K	$10.00K	$0.00	$3.00K
Net Income	$14.19M	-$196.29M	-$57.89M	-$91.72M
Diluted EPS	0.95	-11.02	-2.64	—
Diluted Shares	14.98M	17.81M	21.89M	—

CELU Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$13.97M	$227.00K	$738.00K	$6.17M
Receivables	$6.97M	$12.12M	$13.56M	$4.65M
Inventory	$5.31M	$5.75M	$5.41M	$571.00K
Current Assets	$33.50M	$19.79M	$20.56M	$12.32M
Total Assets	$401.07M	$143.89M	$132.68M	$107.33M
Current Liabilities	$62.09M	$67.30M	$53.68M	$80.76M
Long-Term Debt	—	—	$35.93M	—
Total Debt	$65.59M	$65.42M	$68.84M	$40.90M
Total Liabilities	$202.16M	$102.93M	$123.84M	$145.39M
Retained Earnings	-$645.50M	-$841.79M	-$899.68M	-$991.48M
Shareholders' Equity	$198.90M	$40.96M	$8.84M	-$38.06M
Working Capital	-$28.59M	-$47.51M	-$33.12M	-$68.44M
Net Debt	$23.64M	$39.01M	$41.55M	$7.83M

CELU Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$137.88M	-$38.69M	-$6.40M	-$13.25M
Capital Expenditure	-$5.24M	-$4.05M	-$161.00K	—
Free Cash Flow	-$143.11M	-$42.73M	-$6.56M	-$13.25M
Depreciation & Amortisation	$9.44M	$9.32M	$7.92M	$7.29M
Stock-Based Compensation	$15.86M	$15.02M	$11.57M	$10.38M
Investing Cash Flow	-$5.24M	-$4.05M	$514.00K	$0.00
Financing Cash Flow	$119.84M	$24.09M	$6.70M	$18.65M
Dividends Paid	—	—	$0.00	-$5.90M
Net Change in Cash	-$23.27M	-$18.64M	$814.00K	$5.39M

CELU Income statement, quarterly periods, in USD
USD	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025
Revenue	$18.13M	$11.43M	$5.74M	$5.28M	$4.10M
Cost of Revenue	$7.34M	$3.55M	$5.24M	$3.90M	$7.37M
Gross Profit	$10.79M	$7.87M	$494.00K	$1.38M	-$3.27M
Research & Development	$3.83M	$3.73M	$3.35M	$4.60M	$3.35M
Selling, General & Admin	$16.06M	$14.26M	$12.63M	$9.31M	$15.06M
Operating Expenses	$20.26M	$18.36M	$16.36M	$14.28M	$18.79M
Operating Income	-$9.47M	-$10.49M	-$15.86M	-$12.90M	-$22.06M
EBITDA	-$9.61M	-$15.48M	-$20.75M	-$19.77M	-$21.66M
Pretax Income	-$13.29M	-$19.75M	-$24.52M	-$23.08M	-$24.36M
Income Tax	$0.00	$0.00	$0.00	$0.00	$3.00K
Net Income	-$13.29M	-$19.75M	-$24.52M	-$23.08M	-$24.36M
Diluted EPS	—	-0.84	-1.02	-0.88	—
Diluted Shares	—	23.53M	24.02M	26.35M	—

CELU Balance Sheet statement, quarterly periods, in USD
USD	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025
Cash & Equivalents	$738.00K	$293.00K	$863.00K	$120.00K	$6.17M
Receivables	$13.56M	$14.97M	$11.15M	$6.71M	$4.65M
Inventory	$5.41M	$6.20M	$4.41M	$2.56M	$571.00K
Current Assets	$20.56M	$22.08M	$17.26M	$10.60M	$12.32M
Total Assets	$132.68M	$128.88M	$120.28M	$114.24M	$107.33M
Current Liabilities	$53.68M	$58.69M	$69.23M	$65.31M	$80.76M
Long-Term Debt	$35.93M	$36.49M	$36.49M	—	—
Total Debt	$68.84M	$69.78M	$70.15M	$66.76M	$40.90M
Total Liabilities	$123.84M	$134.38M	$145.78M	$134.33M	$145.39M
Retained Earnings	-$899.68M	-$919.50M	-$944.02M	-$967.10M	-$991.48M
Shareholders' Equity	$8.84M	-$5.51M	-$25.50M	-$20.09M	-$38.06M
Working Capital	-$33.12M	-$36.61M	-$51.96M	-$54.72M	-$68.44M
Net Debt	$41.55M	$42.85M	$42.57M	$4.16M	$7.83M

CELU Cash Flow statement, quarterly periods, in USD
USD	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025
Operating Cash Flow	$1.59M	-$2.99M	-$999.00K	-$4.16M	-$5.10M
Capital Expenditure	-$56.00K	—	—	—	—
Free Cash Flow	$1.54M	-$2.99M	-$999.00K	-$4.16M	-$5.10M
Depreciation & Amortisation	$1.88M	$1.83M	$1.83M	$1.82M	$1.80M
Stock-Based Compensation	$3.10M	$2.64M	$2.45M	$2.04M	$3.25M
Investing Cash Flow	-$1.56M	$0.00	$0.00	$0.00	$0.00
Financing Cash Flow	$643.00K	$2.32M	$1.63M	$3.48M	$11.22M
Dividends Paid	—	—	—	—	$0.00
Net Change in Cash	$681.00K	-$673.00K	$632.00K	-$681.00K	$6.12M

Market Snapshot

About

Celularity Inc. is a clinical-stage biotechnology company developing off-the-shelf cellular therapies derived from the postpartum human placenta, headquartered in Florham Park, New Jersey. The company's technology platform utilizes placental tissue to create allogeneic cell therapies that may be used across multiple patients without requiring individual customization. Celularity's pipeline includes product candidates for hematologic malignancies, solid tumors, infectious diseases, and degenerative diseases. The company is advancing several clinical programs, including treatments for acute myeloid leukemia and COVID-19. Celularity's approach leverages the unique properties of placental cells, which have immunomodulatory and regenerative capabilities. The company aims to develop scalable, accessible cellular therapies that can address significant unmet medical needs while reducing manufacturing complexity compared to autologous cell therapies.